Read Researcher Dr. Matthew Triolo’s Early-Career Blog

Read the latest early-career blog post, from NMD4C member and researcher Dr. Matthew Triolo.

 

I always try to get one message across – although this was not my initial dream, it stemmed from a series of lived experiences, as you will see below. Ultimately, I learned that life and career aspirations are malleable, they change based on the experiences we have and the blending of interests from different realms of our life.

 

Dr. Matthew Triolo is a Postdoctoral Fellow working within Dr. Mireille Khacho’s lab in the Faculty of Medicine at the University of Ottawa. Matthew first completed his BSc in Kinesiology and Health Science with a Minor in Biology at York University. After completing his MSc investigating whether electrical pulse stimulation can enhance muscle cell activity under the guidance of Dr. Michael Connor, he subsequently worked towards his PhD as a member of the Muscle Health Research Centre at York University. While under the supervision of Dr. David Hood, his work focused on skeletal muscle autophagy, mitophagy and lysosome biogenesis in the context of aging, disuse, and exercise. As a new Postdoctoral Fellow, Dr. Triolo is investigating mechanisms by which mitochondria regulate muscle stem cell homeostasis and function. He enjoys playing a variety of sports including hockey, golf and baseball, and spending time with his family, friends, and cat, Luna.

 

Dr. Matt Triolo EC Blog - email

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.